Research programme: antibacterials - eXegenics
Alternative Names: Antibacterials research programme - eXegenics; EXEG 1706Latest Information Update: 13 Jul 2007
At a glance
- Originator eXegenics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Tuberculosis
Most Recent Events
- 13 Mar 2007 eXegenics has merged with Acuity Pharmaceuticals and Froptix Corporation forming Opko Health
- 18 Aug 2003 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 18 Aug 2003 Discontinued - Preclinical for Tuberculosis in USA (unspecified route)